Importantly, the antigen-specific killing of decitabine-treated ovarian cancer cells is not impaired by the presence of the drug, and optimal dosing regimens (1 μM Daily for 5–8 days) have been established to maximize CSPG4 expression [210]. The gene discussed is CSPG4; the disease is ovarian cancer.